Results 61 to 70 of about 94,588 (272)
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
, 2016 Objectives: To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT). Materials and Methods: Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were ...
Gürkan Erdoğan +3 more
core +1 more source
Acta Ophthalmologica, EarlyView.Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco +2 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan +12 more
wiley +1 more source
Rapid “epiretinal membrane” development following intravitreal bevacizumab for Coats' disease
American Journal of Ophthalmology Case Reports, 2018 Purpose: To report a case of rapid “epiretinal membrane” (“ERM”) development following intravitreal bevacizumab for juvenile Coats' disease. Observations: A 7-year old boy was followed for four years with asymptomatic stage 2 Coats' disease in his left ...
Andrew W. Kam +3 more
doaj +1 more source
Indian Journal of Ophthalmology, 2020 We report the successful use of intravitreal bevacizumab in the iatrogenic choroidal neovascular membrane (CNVM) following vitreoretinal surgery. A 69-year-old male underwent vitrectomy surgery with silicone oil (SO) tamponade for rhegmatogenous retinal ...
Ramya Appanraj +4 more
doaj +1 more source
Retina, 2016 Purpose: To compare intravitreal bevacizumab monotherapy with intravitreal dexamethasone delayed delivery system monotherapy for persistent diabetic macular edema.
Sanket U. Shah +3 more
semanticscholar +1 more source
Intravitreal bevacizumab for posterior capsule neovascularization
Saudi Journal of Ophthalmology, 2010 We report a case of rapid regression of extensive posterior capsule neovascularization in a 67-year-old diabetic male patient, who developed posterior capsule opacity with neovascularization one year post cataract surgery, after a single injection of intravitreal bevacizumab (Avastin) followed by neodymium:YAG capsulotomy.
Al-Mohaimeed, Mansour +2 more
openaire +2 more sources
Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola +3 more
wiley +1 more source
Medicina, 2021 The efficacy of combined intravitreal bevacizumab injection with systemic chemotherapy, palliative radiotherapy, and hormonal therapy to treat choroidal and orbital metastases is not known.
I-Hung Lin, Bo-I Kuo, Fang-Yu Liu
doaj +1 more source